source
- Melanoma vaccine shows 42% risk reduction at ESMO 2026, but shares tumble on early data releaseModerna and Merck presented Phase 3 results for their melanoma vaccine intismeran autogene at the European Society for Medical Oncology meeting. The trial reported a 42% reduction in the relative r…
- Genmab’s Rina-S ADC cuts risk of progression and death in Phase 3 ovarian cancer trialGenmab reported results from its Phase 3 RAINFOL-02 trial of the FRα‑directed antibody‑drug conjugate Rina‑S (rinatabart sesutecan) in patients with platinum‑resistant ovarian cancer. In the inten…